相关实验视频

Updated: Feb 28, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

[抗血管治疗在瘤免疫微环境中的作用]

Minoru Kobayashi¹, Satoru Miura

¹Dept. of Internal Medicine, Niigata Cancer Center Hospital.

Gan to kagaku ryoho. Cancer & chemotherapy

|February 26, 2026

概括

血管内皮生长因子 (VEGF) 驱动瘤血管生成,并影响瘤免疫微环境,影响癌症免疫逃避和免疫疗法的有效性. 与免疫检查点抑制剂 (ICI) 结合的抗VEGF疗法在癌症治疗中显示出有前途.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

血管新生在瘤生物学中至关重要,主要是由血管内皮生长因子 (VEGF) 驱动的.
VEGF不仅通过新的血管形成促进瘤生长,而且还显著影响瘤免疫微环境.
VEGF的作用扩展到损害免疫细胞功能和促进免疫抑制细胞,有助于瘤免疫逃避.

研究的目的:

审查抗VEGF治疗对瘤免疫力的影响.
评估与免疫检查点抑制剂 (ICI) 结合抗VEGF治疗的疗效.
根据临床前和临床发现,讨论抗VEGF治疗在癌症治疗中的未来前景.

主要方法:

对抗VEGF治疗的临床前模型和临床研究的审查.
分析VEGF对树突细胞成熟和抗原呈现能力的影响.
研究VEGF在调动免疫抑制细胞 (Tregs,MDSCs) 和抑制效应性T细胞中的作用.

主要成果:

通过抑制抗瘤免疫力,VEGF显著影响瘤免疫微环境.
抗VEGF疗法在调节瘤免疫格局方面显示出潜力.
抗VEGF药物与ICI的联合治疗可能会增强抗瘤反应.

结论:

在癌症中,VEGF扮演着多方面的角色,影响血管生成和免疫逃避.
向VEGF提供了一个克服瘤诱导免疫抑制的策略.
与ICI结合抗VEGF治疗是改善癌症治疗疗效的有希望的途径.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...